PRMT1 suppresses anti-tumor immunity

PRMT1 is known as a regulator of immune function by directly interacting with interferon receptors, methylating STAT1, and promoting B cell and macrophage differentiation by methylating CDK4 or B cell antigen receptor However, the function of PRMT1 as a therapeutic target of cancer remains largely elusive, particularly for its role in cancer immunosurveillance. Here, we performed bulk RNA-seq for CT26, a mouse tumor cell line, after either knocking down of endogeneous Prmt1 or blocking PRMT1 by two specific inhibitors, namely MS023 and GSK3368715. Overall design: Two series of experiments were included, namely Prmt1 knockdown and PRMT1inhibition. For Prmt1 knockdown, there are two groups (shControl and shPrmt1) with 3 biological replicates for each group. For PRMT1 inhibition, there are three groups (Control, MS023 and GSK3368715) with 3 biological replicates for each group.